Clinical Trials
393
Active:16
Completed:51
Trial Phases
6 Phases
Early Phase 1:4
Phase 1:16
Phase 2:86
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (219 trials with phase data)• Click on a phase to view related trials
Phase 2
86 (39.3%)Not Applicable
76 (34.7%)Phase 3
22 (10.0%)Phase 1
16 (7.3%)Phase 4
15 (6.8%)Early Phase 1
4 (1.8%)Modulating the Skin Microbiome to Prevent Radiation Dermatitis in Breast Cancer
Not Applicable
Recruiting
- Conditions
- Skin MicrobiomeRadiation DermatitisBreast Cancer
- Interventions
- Drug: Skin Repairing CreamOther: Cetaphil® Moisturizing Cream as Inactive Control
- First Posted Date
- 2025-07-15
- Last Posted Date
- 2025-07-15
- Target Recruit Count
- 326
- Registration Number
- NCT07066280
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China
Study on Heart Block Risks Using Outcome-Based Modeling
Completed
- Conditions
- Left Bundle-Branch BlockAortic Stenosis
- First Posted Date
- 2025-07-15
- Last Posted Date
- 2025-07-15
- Target Recruit Count
- 112
- Registration Number
- NCT07065123
Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
Not Applicable
Not yet recruiting
- Conditions
- Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
- Interventions
- Drug: Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qdDrug: Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bidDrug: Palbociclib 200mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid
- First Posted Date
- 2025-07-11
- Last Posted Date
- 2025-07-11
- Target Recruit Count
- 474
- Registration Number
- NCT07061717
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
Efficacy and Prognosis of Microwave Ablation Treatment for Papillary Thyroid Microcarcinoma Assessed by Contrast-Enhanced Ultrasound Combined With Genetic and Molecular Diagnostics: A Prospective Observational Study
Recruiting
- Conditions
- Microwave AblationContrast-enhanced UltrasoundGenetic and Molecular DiagnosticsPapillary Thyroid Microcarcinoma
- Interventions
- Drug: Contrast enhanced UltrasoundGenetic: 88-gene panel for thyroid cancer
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Target Recruit Count
- 480
- Registration Number
- NCT07054229
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Bladder Cancer Staging and Prediction of New Adjuvant Chemotherapy Efficacy Based on Deep Learning and Transfer Learning in Ultrasound-Magnetic Resonance-Pathology Multimodal Multiscale
Recruiting
- Conditions
- StagingNeoadjuvant ChemotherapyContrast Enhanced UltrasoundDeep LearningBladder Cancer
- First Posted Date
- 2025-07-03
- Last Posted Date
- 2025-07-03
- Target Recruit Count
- 480
- Registration Number
- NCT07051083
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 79
- Next
News
No news found